AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Recursion Pharmaceuticals... (RXRX)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

10.59

0.06 (0.57%)

At close: Feb 18, 2025, 3:59 PM

10.73

1.32%

After-hours: Feb 18, 2025, 07:59 PM EST

undefined% (undefined)

Bid	10.72
Market Cap	4.06B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-1.54
PE Ratio (ttm)	-6.88
Forward PE	n/a
Analyst	Buy

Ask	10.73
Volume	68,494,652
Avg. Volume (20D)	19,303,401
Open	11.55
Previous Close	10.53
Day's Range	10.41 - 12.36
52-Week Range	5.60 - 15.74
Beta	undefined

About RXRX

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Apr 16, 2021

Employees 500

Stock Exchange NASDAQ

Ticker Symbol RXRX

Website https://www.recursion.com

Full Company Profile

Analyst Forecast

According to 4 analyst ratings, the average rating for RXRX stock is "Buy." The 12-month stock price forecast is $9, which is a decrease of -15.01% from the latest price.

Buy 50.00%

Hold 50.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Recursion Pharmaceuticals Inc. is scheduled to release its earnings on Mar 4, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

5 days ago

+23.88%

Recursion Pharmaceuticals shares are trading highe... Unlock content with Pro Subscription

5 months ago

Recursion Pharmaceuticals shares are trading lower. The company announced top-line results of the SYCAMORE trial for REC-994 in symptomatic CCM patients.

News

22 hours ago · zacks.com

Recursion Pharmaceuticals Before Q4 Earnings: How to Play the Stock

RXRX is expected to provide updates on its oncology and rare disease pipeline in its fourth-quarter earnings release, given the absence of a marketed product.

23 hours ago · fool.com

25 Top AI Stocks That Could Boost Your Portfolio

The artificial intelligence (AI) revolution is reshaping the global economy at an unprecedented pace, with innovations emerging across every sector from healthcare to transportation. As companies race...

4 days ago · fool.com

Why Recursion Pharmaceuticals Stock Is Soaring Today

Shares of Recursion Pharmaceuticals (RXRX 16.12%) had soared by 15.8% as of 12:06 p.m. ET on Friday.

5 days ago · marketbeat.com

Biotechs on the Brink: 2 Stocks With Huge Potential

Investors know the biotech industry is a waiting game—smaller companies in this space often work to secure the funding to keep their doors open during a pre-revenue period while they develop drug trea...

6 days ago · zacks.com

Recursion Pharmaceuticals (RXRX) Laps the Stock Market: Here's Why

In the most recent trading session, Recursion Pharmaceuticals (RXRX) closed at $8.50, indicating a +1.92% shift from the previous trading day.

6 days ago · seekingalpha.com

Recursion: CDK7 Inhibitor Differentiation Is Initially Paying Off

Company is advancing REC-617, a promising reversible, non-covalent CDK7 inhibitor, showing potential in treating advanced solid tumors with positive interim phase 1 data. The company is also progressi...

6 days ago · zacks.com

Recursion Pharmaceuticals (RXRX) Stock Jumps 8.9%: Will It Continue to Soar?

Recursion Pharmaceuticals (RXRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in ...

1 week ago · zacks.com

Recursion Pharmaceuticals (RXRX) Exceeds Market Returns: Some Facts to Consider

Recursion Pharmaceuticals (RXRX) closed at $7.66 in the latest trading session, marking a +0.13% move from the prior day.

2 weeks ago · zacks.com

Recursion Pharmaceuticals (RXRX) Ascends While Market Falls: Some Facts to Note

The latest trading day saw Recursion Pharmaceuticals (RXRX) settling at $7.25, representing a +0.14% change from its previous close.

2 weeks ago · 247wallst.com

Cathie Wood's Top Biotech Plays for February

Don't look now, but Cathie Wood of Ark Invest is fresh off an impressive comeback year, with her broader basket of disruptive technology funds posting high double-digit percentage returns.

Load More News